<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899427</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-NHL-009</org_study_id>
    <nct_id>NCT04899427</nct_id>
  </id_info>
  <brief_title>Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma: a Prospective Multi-center Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Renmin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Province Renmin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Forth Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter single-arm phase II study, and the purpose of this study is&#xD;
      to evaluate the efficiency of Orelabrutinib combined with PD-1 inhibitor regimen&#xD;
      relapsed/refractory primary intraocular lymphoma. Overall response rate （ORR） after 4 cycles&#xD;
      is the primary endpoint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients will be treated with Orelabrutinib combined with PD-1 inhibitor&#xD;
      ：Orelabrutinib 150mg qd，Tislelizumab Injection 200mg d1 or Sintilimab injection 200mg d1，&#xD;
      every 21-day for 1 cycle). Patients will be evaluated every 2 cycles by MRI scan during the&#xD;
      first 6 cycles，and then the interval of investigation will be prolonged to 12 weeks. The&#xD;
      patients who achieved complete remission (CR) or partial remission (PR) or stable disease&#xD;
      (SD) will receive further treatment. The patients progressed disease (PD) will withdraw from&#xD;
      the trial and receive salvage regimens. The treatment will be continued for 2 years or until&#xD;
      progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.&#xD;
&#xD;
      During following-up, surveillance ophthalmologic examination and brain magnetic resonance&#xD;
      imaging (MRI) scans can be performed every 3 months up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">October 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>3 weeks after the end of 4 cycles of induction (each cycle is 21 days)</time_frame>
    <description>ORR was calculated by the proportion of patients who achieved complete remission and partial remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 years progression-free survival</measure>
    <time_frame>from the date of treatment to the subject finished his 1 years follow-up phase or the disease relapsed or the death due to lymphoma</time_frame>
    <description>1 years progression-free survival was calculated from the date of therapy until death from lymphoma or 1-year follow up without relapsing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>orelabrutinib combined with PD-1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm will be treated orelabrutinib plus PD-1(programmed death）inhibitor every 21 days as one cycle. The responses will be evaluated every 2 cycles during the first 6 cycles and every 3 months until progression.&#xD;
The investigators can choose Sintilimab Injection or Tislelizumab Injection at the beginning of treatment，but they can't exchange to another during the whole treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>orelabrutinib</intervention_name>
    <description>Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.</description>
    <arm_group_label>orelabrutinib combined with PD-1 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.</description>
    <arm_group_label>orelabrutinib combined with PD-1 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.</description>
    <arm_group_label>orelabrutinib combined with PD-1 inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old ≤75 Years old, male or female&#xD;
&#xD;
          -  Primary Central nerves system lymphoma confirmed by cytology or histology according to&#xD;
             WHO2016 criteria&#xD;
&#xD;
          -  No evidence of systemic lymphoma&#xD;
&#xD;
          -  Patients with a clear diagnosis of relapsed and/or refractory PCNSL: they received at&#xD;
             least one regimen containing methotrexate.&#xD;
&#xD;
          -  At least one measurable lesion according to Lugano 2014 criteria&#xD;
&#xD;
          -  Adequate organ function and adequate bone marrow reserve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignant tumors other than B-NHL within 5 years prior to screening, except cervical&#xD;
             carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer&#xD;
             after radical surgery, and breast ductal carcinoma in situ after radical surgery&#xD;
&#xD;
          -  Active HIV, HBV, HCV or treponema pallidum infection&#xD;
&#xD;
          -  Any instability of systemic disease, including but not limited to active infection&#xD;
             (except local infection), severe cardiac, liver, kidney, or metabolic disease need&#xD;
             therapy&#xD;
&#xD;
          -  Female subjects who have been pregnant or breastfeeding, or who plan to conceive&#xD;
             during or within 1 year after treatment, or male subjects' partner plans to conceive&#xD;
             within 1 year after their cell transfusion&#xD;
&#xD;
          -  Active or uncontrolled infections requiring systemic treatment within 14 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Any systemic antitumor therapy performed within 2 weeks before enrollment&#xD;
&#xD;
          -  Previous use of other BTK inhibitors or PD-1 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wei Zhang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang</last_name>
      <phone>13681473557</phone>
      <email>vv1223@vip.sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Central Nervous System Lymphoma</keyword>
  <keyword>orelabrutinib</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>Overall response rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

